<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1010339</article-id><article-id pub-id-type="publisher-id">ACM-38071</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201000000_40230556.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  索拉非尼在原发性肝癌治疗中的临床研究进展
  Sorafenib in the Treatment of Hepatocellular Carcinoma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姚</surname><given-names>欣</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>建军</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院肿瘤介入科，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>10</day><month>10</month><year>2020</year></pub-date><volume>10</volume><issue>10</issue><fpage>2241</fpage><lpage>2245</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    分子靶向治疗在原发性肝癌(hepatocellular carcinoma, HCC)治疗中起重要作用，目前，新型多靶点抗肿瘤药物索拉非尼是关键的靶向治疗药物之一。它具有双重的抗肿瘤作用：既可通过阻断由RAF/MEK/ERK介导的细胞信号传导通路而直接抑制肿瘤细胞的增殖，还可通过抑制VEGFR和血小板衍生生长因子(PDGF)受体而阻断肿瘤新生血管的形成，间接地抑制肿瘤细胞的生长。索拉非尼联合免疫治疗晚期原发性肝癌有一定前景。本文就索拉非尼在原发性肝癌治疗中的相关临床研究进展作一综述。
    Molecular targeted therapy plays an important role in the treatment of primary liver cancer (hepatocellular carcinoma, HCC). At present, the new multi-target anti-tumor drug sorafenib is one of the key targeted therapy drugs. It has a dual anti-tumor effect: it can directly inhibit the proliferation of tumor cells by blocking the cell signaling pathway mediated by RAF/MEK/ERK, and it can also inhibit VEGFR and platelet-derived growth factor (PDGF) receptors, block the formation of tumor blood vessels and indirectly inhibit the growth of tumor cells. Sorafenib combined with immunotherapy has certain prospects for advanced primary liver cancer. This article reviews the progress of sorafenib in the treatment of primary liver cancer. 
  
 
</p></abstract><kwd-group><kwd>原发性肝癌，HCC，索拉非尼，靶向治疗，免疫治疗, Hepatocellular Carcinoma</kwd><kwd> HCC</kwd><kwd> Sorafenib</kwd><kwd> Targeted Therapy</kwd><kwd> Immunity Therapy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>分子靶向治疗在原发性肝癌(hepatocellular carcinoma, HCC)治疗中起重要作用，目前，新型多靶点抗肿瘤药物索拉非尼是关键的靶向治疗药物之一。它具有双重的抗肿瘤作用：既可通过阻断由RAF/MEK/ERK介导的细胞信号传导通路而直接抑制肿瘤细胞的增殖，还可通过抑制VEGFR和血小板衍生生长因子(PDGF)受体而阻断肿瘤新生血管的形成，间接地抑制肿瘤细胞的生长。索拉非尼联合免疫治疗晚期原发性肝癌有一定前景。本文就索拉非尼在原发性肝癌治疗中的相关临床研究进展作一综述。</p></sec><sec id="s2"><title>关键词</title><p>原发性肝癌，HCC，索拉非尼，靶向治疗，免疫治疗</p></sec><sec id="s3"><title>Sorafenib in the Treatment of Hepatocellular Carcinoma</title><p>Xin Yao, Jianjun Yang<sup>*</sup></p><p>Department of Interventional Oncology, Affiliated Hospital of Yan’an University, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/6-1571607x4_hanspub.png" /></p><p>Received: Sep. 23<sup>rd</sup>, 2020; accepted: Oct. 8<sup>th</sup>, 2020; published: Oct. 15<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/6-1571607x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Molecular targeted therapy plays an important role in the treatment of primary liver cancer (hepatocellular carcinoma, HCC). At present, the new multi-target anti-tumor drug sorafenib is one of the key targeted therapy drugs. It has a dual anti-tumor effect: it can directly inhibit the proliferation of tumor cells by blocking the cell signaling pathway mediated by RAF/MEK/ERK, and it can also inhibit VEGFR and platelet-derived growth factor (PDGF) receptors, block the formation of tumor blood vessels and indirectly inhibit the growth of tumor cells. Sorafenib combined with immunotherapy has certain prospects for advanced primary liver cancer. This article reviews the progress of sorafenib in the treatment of primary liver cancer.</p><p>Keywords:Hepatocellular Carcinoma, HCC, Sorafenib, Targeted Therapy, Immunity Therapy</p><disp-formula id="hanspub.38071-formula28"><graphic xlink:href="//html.hanspub.org/file/6-1571607x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/6-1571607x8_hanspub.png" /> <img src="//html.hanspub.org/file/6-1571607x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>肝细胞癌是最常见的原发性肝癌，是全球范围内与癌症相关的死亡的主要原因 [<xref ref-type="bibr" rid="hanspub.38071-ref1">1</xref>]。它是全球第三大最常见的癌症死亡原因，每年导致70万多人死亡 [<xref ref-type="bibr" rid="hanspub.38071-ref2">2</xref>]。根据2017年中国肝移植注册网(CTLR)最新数据显示我国肝癌的发病率为20~40人/10万人，病例数占全球总数一半，每年约30万患者死于肝癌。肝癌目前占我国癌症死因的第二位。我国肝癌的发病特点大多遵循乙型肝炎–肝硬化–肝癌的“三步曲”模式 [<xref ref-type="bibr" rid="hanspub.38071-ref3">3</xref>]。其具有发病率高、病情进展快、易反复发作、病灶易转移等特点，且病死率较高。手术是治疗原发性肝癌的有效方法，但大多患者确诊时已属肝癌晚期，失去手术治疗的最佳时机，因此需要联合其他方法治疗。分子靶向治疗的进展为该疾病带来了显著的疗效。2007年，索拉非尼成为首个获得美国食品和药物管理局(FDA)批准的用于HCC的一线全身治疗药物。索拉非尼提供了多个治疗部位作用，抑制血管内皮生长因子受体1 (VEGFR1)，VEGFR2，VEGFR3，血小板源性生长因子受体β (PDGFR-β)和RAFfamily激酶。在Boland等 [<xref ref-type="bibr" rid="hanspub.38071-ref4">4</xref>] 研究者具有里程碑意义的III期SHARP试验中，602例主要是Child Pugh分级A级的HCC患者，索拉非尼改善中位总生存期(mOS)与安慰剂相比(10.7 vs. 7.9个月；P &lt; 0.001)，有统计学差异。赵莉等 [<xref ref-type="bibr" rid="hanspub.38071-ref5">5</xref>] 人评估索拉非尼在接受HCC切除术的患者中的治疗价值。索拉非尼的使用：RFS (无复发生存期)显著升高(HR = 0.53; 95%CI, 0.31~0.90; p = 0.018)和较低的复发率(风险比[RR] = 0.72；95%CI，0.60~0.86；p &lt; 0.001)和死亡率(RR = 0.74; 95%CI, 0.57~0.95; p = 0.20)。结果表明索拉非尼在RFS，复发率和死亡率方面显示出显著优势。本文参考相关资料，讨论索拉非尼在原发性肝癌治疗中的相关临床研究进展。</p></sec><sec id="s6"><title>2. 索拉非尼的作用机制</title><p>癌症进展、生长和扩散所必须的条件是血管生成和血液供应，破坏内皮细胞反应可以阻止肿瘤的生长。而VEGFR酪氨酸激酶信号通路促进血管内皮细胞增殖，在肿瘤的发生、发展和转移过程中起到了至关重要的作用。索拉非尼通过靶向RAF/MEK/ERK途径和受体酪氨酸激酶来抑制肿瘤生长和血管生成 [<xref ref-type="bibr" rid="hanspub.38071-ref6">6</xref>]。这一作用机制已被很好的表证，但刘刚等 [<xref ref-type="bibr" rid="hanspub.38071-ref7">7</xref>] 研究表明索拉非尼也可通过ATP-AMPK-mTOR-SREBP1信号通路破坏SCD1介导的单不饱和脂肪酸的合成来杀死肝癌细胞。另外，索拉非尼与中药冬凌草的核心生物活性成分奥利多宁联用也可以抑制HCC细胞，Xuguang Li等 [<xref ref-type="bibr" rid="hanspub.38071-ref8">8</xref>] 的基础研究证实奥利多宁联合索拉非尼可通过靶向Akt途径而非NF-κB或MAPK信号传导协同抑制增殖，迁移，侵袭和上皮间质转化并诱导凋亡。</p><p>Tim A.等 [<xref ref-type="bibr" rid="hanspub.38071-ref9">9</xref>] 在多中心II期研究(SORAMIC)中前瞻性招募了晚期HCC患者。包括74名患者，中位OS为19.7个月(95% CI 16.1~23.3)。患者接受索拉非尼治疗的中位时间为51周(IQR 27~62)，中位接受治疗的血液样本的中位时间为25周(IQR 10~42)。患者的平均谷浓度为3217 ng/ml (IQR 2166~4526)和360 ng/ml (IQR 190~593)，索拉非尼和M2的变异系数分别为65%和146%。经历严重的索拉非尼相关毒性反应的患者接受的平均每日剂量较低(551 vs 730 mg/天，p = 0.003)，但索拉非尼(3298 vs. 2915 ng/ml, p = 0.442)或M2低谷水平(428 vs. 283 ng/ml, p = 0.159)无明显差异。即索拉非尼或M2的低谷水平与OS没有显著相关性。毒性调整剂量仍然是索拉非尼治疗的标准。</p></sec><sec id="s7"><title>3. 索拉非尼的耐药性</title><p>原发性肝癌(HCC)是一种全球普遍存在的恶性肿瘤，患者预后较差。索拉非尼用于治疗难以手术的晚期原发性肝癌确实有一定的疗效，但它的耐药性也不容忽视。耐药可分为原发性(HCC原本就对索拉非尼缺乏敏感性)和获得性(开始敏感，治疗过程中出现耐药)两类，其机制尚不清楚。HCC对索拉菲尼的耐药机制主要表现在肝癌细胞自身和肿瘤微环境两个方面：前者包括细胞自噬、上皮–间质转化(epithelial-mesenchymal transition, EMT)、铁死亡(ferroptosis)受抑制和肿瘤起始细胞(tumor-initiating cell, TIC)等；后者包括外泌体(exosome)和血管选定等 [<xref ref-type="bibr" rid="hanspub.38071-ref10">10</xref>]。</p><p>在唐小凤等 [<xref ref-type="bibr" rid="hanspub.38071-ref11">11</xref>] 研究中，使用逆转录定量PCR在具有不同索拉非尼敏感性的HCC细胞系中确定了miR-223的表达。将miR-223抑制剂，miR-223模拟物以及包含F-box和WD重复域的7个(FBW7)短干扰RNA (siRNA)转染到HCC细胞中，以调节miR-223和FBW7的表达水平。使用乙炔基脱氧尿苷(EdU)掺入分析和Cell Counting Kit-8评估细胞增殖。使用蛋白质印迹观察到FBW7蛋白表达水平。在具有索拉非尼耐药的HCC细胞中，miR-223表达增加。这表明miR-223可能是新的治疗靶点克服索拉非尼耐药性。</p></sec><sec id="s8"><title>4. 索拉非尼的不良反应</title><p>刘国锟等 [<xref ref-type="bibr" rid="hanspub.38071-ref12">12</xref>] 选取61例Child-Pugh A级或B级的晚期肝癌患者，予以索拉非尼治疗，周期为6个月。记录治疗前、治疗2个月后及治疗6个月后患者的一般资料、血常规、肝肾功能、AFP、腹水、CT增强扫描及不良反应，进行疗效及安全性判定。结果显示43例(70.5%)患者出现药物相关的不良反应，主要不良反应为轻度的手足皮肤综合征40例(65.57%)、肢体乏力27例(44.26%)。全部患者疾病进展时间(TTP)的中位数为3.9个月(95% CI: 2.9~4.5)。不良反应及中位TTP在Child-Pugh A，B级组间无显著差异。虽然索拉菲尼能有效提高晚期肝癌患者的生存质量，但需要注意预防不良反应。</p><p>索拉非尼是一种多靶点酪氨酸激酶抑制剂，手足皮肤反应(hand-foot skin reaction HFSR)作为最常见的不良反应之一，阻碍了其长期临床应用 [<xref ref-type="bibr" rid="hanspub.38071-ref13">13</xref>]。目前，其发生机理尚未得到明确研究，导致缺乏有效的干预手段。在不了解HFSR的机制的情况下，索拉非尼诱导的HFSR临床治疗的最常见方法是剂量下调或中止治疗，这会影响疗效甚至生存。王平等 [<xref ref-type="bibr" rid="hanspub.38071-ref14">14</xref>] 研究者通过系统评价和荟萃分析，审查了1478篇文章，包括1017名参与者的12项队列研究。总体生存的合并风险比(HR)为0.45 (95%置信区间(CI) 0.36，0.55；P &lt; 0.00001；I2 = 35%)。进展时间的合并HR为0.41 (95%CI 0.28, 0.60; P &lt; 0.00001; I2 = 0%)。患有HFSR的患者比没有HFSR的患者索拉非尼治疗的转归明显更好。结果表明HFSR是接受索拉非尼治疗的肝癌患者的有益指标。然而，HFSR与HCC对索拉非尼的反应之间的关系仍不清楚。仍然存在解释索拉非尼诱导的HCC患者HFSR的分子机制的问题。</p></sec><sec id="s9"><title>5. 索拉非尼联合免疫治疗</title><p>免疫检查点负性调节免疫系统导致机体形成免疫抑制性肿瘤微环境，使得肿瘤细胞有机会逃避机体免疫监视及杀伤。程序性死亡1 (PD-1)是一种细胞表面受体，可作为T细胞检查点，并在调节T细胞衰竭中起核心作用。PD-1与其配体，程序性死亡配体1 (PD-L1)的结合可激活下游信号通路并抑制T细胞活化。而且，在肿瘤微环境中肿瘤细胞和抗原呈递细胞上异常高的PD-L1表达介导肿瘤免疫逃逸，并且抗PD-1/PD-L1抗体的开发近来已成为癌症免疫治疗中的热门话题 [<xref ref-type="bibr" rid="hanspub.38071-ref15">15</xref>]。</p><p>Voutsadakis [<xref ref-type="bibr" rid="hanspub.38071-ref16">16</xref>] 的三项研究(两项针对尼古拉单抗，一项针对派姆单抗)对400名患者进行了分析。总体回应率(RR)为17.3% [95%置信区间(CI)：13.2%~21.4%]。疾病控制率(DCR)为56.6% (95%CI：44.7%~68.5%)。无进展生存期(PFS)为3.5个月(95%CI：2.8~4.2个月)。总体生存期(OS)为10.4个月(95%CI：3.5~17.2个月)。不良反应发生率低，并且与其他疾病部位的PD-L1/PD-1抑制剂的不良反应相一致。其有效性与可用于该疾病的其他全身疗法并无不同。对于无法接受索拉非尼/lenvatinib治疗失败的晚期疾病患者，HCC免疫疗法是相对安全的选择 [<xref ref-type="bibr" rid="hanspub.38071-ref17">17</xref>]。2017年9月，根据多队列1/2期临床试验CheckMate-040的数据，nivolumab在sarafenib失败后被FDA批准用于肝癌的二线治疗 [<xref ref-type="bibr" rid="hanspub.38071-ref18">18</xref>]。段峰等 [<xref ref-type="bibr" rid="hanspub.38071-ref19">19</xref>] 人评估尼古拉单抗抗PD1治疗晚期肝细胞癌(HCC)的疗效和安全性，根据巴塞罗那临床肝癌分期，从2016年1月至2017年1月，对11例HCC (平均年龄为51.8岁)，B期4例，C期7例患者进行了nivolumab治疗。每个患者介于4到18个周期之间。Nivolumab的疾病控制率为81.8%，客观反应为63.6% (改良的实体瘤反应评估标准)。没有观察到与nivolumab有关的不良反应。结果表明nivolumab可以在HCC患者中获得可接受的结果，并且可以作为可选治疗，特别是对于无法从常规治疗中受益的患者。El-Khoueiry A.B.等 [<xref ref-type="bibr" rid="hanspub.38071-ref20">20</xref>] 评估nivolumab在患有或不患有慢性病毒性肝炎的晚期肝细胞癌患者中的安全性和有效性。262位患者中的202位(77%)已完成治疗，并且正在进行随访。在剂量递增期间，nivolumab显示出可控的安全性，包括可接受的耐受性。持久的客观反应显示了nivolumab治疗晚期肝细胞癌的潜力。</p></sec><sec id="s10"><title>6. 展望</title><p>延长患者生存期，让患者在即将到来的生命终点能够比较有质量地生活是晚期肝癌治疗的基本目的。临床上需结合患者的实际情况选择合适的治疗方案，免疫治疗和分子靶向治疗的联合为晚期肝细胞癌的治疗开辟了新天地，为临床医生提供了更多的选择，但还需要大样本多中心的临床试验来证实获益率，从而为临床治疗提供指导。期待在未来的研究中看到免疫治疗的更多潜力。</p></sec><sec id="s11"><title>文章引用</title><p>姚 欣,杨建军. 索拉非尼在原发性肝癌治疗中的临床研究进展Sorafenib in the Treatment of Hepatocellular Carcinoma[J]. 临床医学进展, 2020, 10(10): 2241-2245. https://doi.org/10.12677/ACM.2020.1010339</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38071-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Khemlina, G., Ikeda, S. and Kurzrock, R. (2017) The Biology of Hepatocellular Carcinoma: Implications for Genomic and Immune Therapies. Molecular Cancer, 16, 149. &lt;br&gt;https://doi.org/10.1186/s12943-017-0712-x</mixed-citation></ref><ref id="hanspub.38071-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Arrese, M., Hernandez, A., Astete, L., Estrada, L., Cabello-Verrugio, C. and Cabrera, D. (2018) TGF-β and Hepatocellular Carcinoma: When a Friend Becomes an Enemy. Current Protein &amp; Peptide Science, 19, 1172-1179.  
&lt;br&gt;https://doi.org/10.2174/1389203718666171117112619</mixed-citation></ref><ref id="hanspub.38071-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">夏锋, 李雪松. 肝细胞癌癌前病变的诊断和治疗多学科专家共识(2020版)[J]. 临床肝胆病杂志, 2020, 36(3): 514-518.</mixed-citation></ref><ref id="hanspub.38071-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Boland, P. and Wu, J. (2018) Systemic Therapy for Hepatocellular Carcinoma: Beyond Sorafenib. Chinese Clinical Oncology, 7, 50. &lt;br&gt;https://doi.org/10.21037/cco.2018.10.10</mixed-citation></ref><ref id="hanspub.38071-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Li, Z., Gao, J., Zheng, S.M., et al. (2020) The Efficacy of Sorafenib in Preventing Hepatocellular Carcinoma Recurrence after Resection: A Systematic Review and Meta-Analysis. Revista Espanola de Enfermedades Digestivas, 112, 201-210. &lt;br&gt;https://doi.org/10.17235/reed.2020.6458/2019</mixed-citation></ref><ref id="hanspub.38071-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Abdelgalil, A.A., Alkahtani, H.M. and Al-Jenoobi, F.I. (2019) Sorafenib. Purchase Profiles of Drug Substances, Excipients, and Related Methodology, 44, 239-266. &lt;br&gt;https://doi.org/10.1016/bs.podrm.2018.11.003</mixed-citation></ref><ref id="hanspub.38071-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Liu, G., Kuang, S., Cao, R., Wang, J., Peng, Q. and Sun, C. (2019) Sorafenib Kills Liver Cancer Cells by Disrupting SCD1-Mediated Synthesis of Monounsaturated Fatty Acids via the ATP-AMPK-mTOR-SREBP1 Signaling Pathway. The FASEB Journal, 33, 10089-10103. &lt;br&gt;https://doi.org/10.1096/fj.201802619RR</mixed-citation></ref><ref id="hanspub.38071-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Li, X.G., Chen, W.R., Liu, K.H., et al. (2020) Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway. SJPD117913229757, 2020 (Default), 8081-8091.  
&lt;br&gt;https://doi.org/10.2147/CMAR.S257482</mixed-citation></ref><ref id="hanspub.38071-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Labeur, T.A., Hofsink, Q., Takkenberg, R.B., et al. (2020) The Value of Sorafenib Trough Levels in Patients with Advanced Hepatocellular Carcinoma—A Sub-Study of the SORAMIC Trial. Acta Oncologica, 59, 1028-1035.  
&lt;br&gt;https://doi.org/10.1080/0284186X.2020.1759826</mixed-citation></ref><ref id="hanspub.38071-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">胡倍源, 覃伟, 董琼珠, 钦伦秀. 肝细胞癌(HCC)对索拉非尼耐药相关机制的研究进展[J]. 复旦学报(医学版), 2018, 45(6): 884-888.</mixed-citation></ref><ref id="hanspub.38071-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Tang, X., Yang, W., Shu, Z., et al. (2019) MicroRNA-223 Promotes Hepatocellular Carcinoma Cell Resistance to Sorafenib by Targeting FBW7. Oncology Reports, 41, 1231-1237. &lt;br&gt;https://doi.org/10.3892/or.2018.6908</mixed-citation></ref><ref id="hanspub.38071-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">刘国锟, 郭艳霞. 索拉菲尼治疗晚期肝癌患者的临床疗效和安全性分析[J]. 中国处方药, 2020, 18(7): 77-78.</mixed-citation></ref><ref id="hanspub.38071-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ai, L., Xu, Z., Yang, B., He, Q. and Luo, P. (2019) Sorafenib-Associated Hand-Foot Skin Reaction: Practical Advice on Diagnosis, Mechanism, Prevention, and Management. Expert Review of Clinical Pharmacology, 12, 1121-1127.  
&lt;br&gt;https://doi.org/10.1080/17512433.2019.1689122</mixed-citation></ref><ref id="hanspub.38071-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Wang, P., Tan, G., Zhu, M., Li, W., Zhai, B. and Sun, X. (2018) Hand-Foot Skin Reaction Is a Beneficial Indicator of Sorafenib Therapy for Patients with Hepatocellular Carcinoma: A Systemic Review and Meta-Analysis. Expert Review of Gastroenterology &amp; Hepatology, 12, 1-8. &lt;br&gt;https://doi.org/10.1080/17474124.2017.1373018</mixed-citation></ref><ref id="hanspub.38071-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, Y., Chen, M., Nie, H. and Yuan, Y. (2019) PD-1 and PD-L1 in Cancer Immunotherapy: Clinical Implications and Future Considerations. Human Vaccines &amp; Immunotherapeutics, 15, 1111-1122.  
&lt;br&gt;https://doi.org/10.1080/21645515.2019.1571892</mixed-citation></ref><ref id="hanspub.38071-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Voutsadakis, I.A. (2019) PD-1 Inhibitors Monotherapy in Hepatocellular Carcinoma: Meta-Analysis and Systematic Review. Hepatobiliary &amp; Pancreatic Diseases International, 18, 505-510. &lt;br&gt;https://doi.org/10.1016/j.hbpd.2019.09.007</mixed-citation></ref><ref id="hanspub.38071-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Ghavimi, S., Apfel, T., Azimi, H., Persaud, A. and Pyrsopoulos, N.T. (2020) Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options. Journal of Clinical and Translational Hepatology, 8, 168-176. &lt;br&gt;https://doi.org/10.14218/JCTH.2020.00001</mixed-citation></ref><ref id="hanspub.38071-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Finkelmeier, F., Waidmann, O. and Trojan, J. (2018) Nivolumab for the Treatment of Hepatocellular Carcinoma. Expert Review of Anticancer Therapy, 18, 1169-1175. &lt;br&gt;https://doi.org/10.1080/14737140.2018.1535315</mixed-citation></ref><ref id="hanspub.38071-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Feng, D., et al. (2017) Initial Experience of Anti-PD1 Therapy with Nivolumab in Advanced Hepatocellular Carcinoma. Oncotarget, 8, 96649-96655. &lt;br&gt;https://doi.org/10.18632/oncotarget.20029</mixed-citation></ref><ref id="hanspub.38071-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">El-Khoueiry, A.B., Sangro, B., Yau, T., et al. (2017) Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. The Lancet, 389, 2492-2502. &lt;br&gt;https://doi.org/10.1016/S0140-6736(17)31046-2</mixed-citation></ref></ref-list></back></article>